Original Source(s)
Related Content
FDA approves first therapy for symptomatic dermographism
The oral BTK inhibitor produced a complete hive response in 29.3% of treated patients at week 12.
by Teraya Smith
October 7, 2026
-
2 min
FDA, CMS target gene therapy barriers
FDA and CMS initiatives aim to simplify gene therapy approvals and expand access to treatments for rare diseases.
by Mouj Hijazi
October 29, 2026
-
4 min
FDA approves liquid cevimeline for Sjögren disease
The new oral solution offers an alternative to capsules for adults with dry mouth, including those with swallowing difficulties.
by Mouj Hijazi
October 21, 2026
-
3 min